Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ADR-001 for severe COVID-19 pneumonia
jRCT2053210023Phase 2Recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- May 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ADR-001 in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Ventilator-free days. Started May 2021; status: recruiting.
02
Drugs
ADR-001
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on jRCT2053210023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053210023.